Islexa is built on research from University of Aberdeen, which looked into re-programming normal pancreatic tissue into fully functional islets – clusters of cells that produce insulin.
This technology could offer an alternative to patients with T1D. In this type of diabetes, the immune system attacks the cells that produce insulin – one example of harmful inflammation.
Islexa’s laboratory grown islets are meant to bring islet transplants to more diabetes patients. While this procedure has shown efficacy, there is a shortage of suitable donor organs – and the extraction of islets is also complicated.